Morning

About Us

Ironshore Pharmaceuticals Inc. is a US-based pharmaceutical company whose mission is to commercialize innovative, patient-centric treatment options to improve the lives of patients and caregivers.

What We Do


Based in Morrisville, North Carolina, Ironshore Pharmaceuticals Inc. is responsible for the sales, marketing and distribution of pharmaceutical products within the US. Ironshore Pharmaceuticals Inc. was founded in 2015 and is a wholly owned subsidiary of Toronto-based Highland Therapeutics, Inc.

Ironshore Pharmaceuticals Inc.

Controlled Release

 
430 Davis Drive, Suite 250
Morrisville, NC 27560
United States

Controlled Release

 
2370 State Route 70 West, Suite 309
Cherry Hill, NJ 08002
United States

Leadership


Stephanie Read
Chief Executive Officer

Danny Villeneuve
Chief Commercial Officer

Dr. Randy Sallee
Chief Medical Officer

Lewis E. Warrington, MD
Vice President, Medical Affairs

Nilay Patel
SVP General Counsel, Chief Compliance Officer

Jim Fletcher
VP, Human Resources

Stephanie Read

Stephanie Read serves as Chief Executive Officer of Ironshore Pharmaceuticals.

In addition to serving as the newly appointed CEO of Ironshore, Stephanie will continue to have a seat on the Highland-Ironshore Board. Ms. Read also serves as a Non-Executive Director on the Board of ALSP Orchid Acquisition Corporation I (NASDAQ:ALORU). Ms. Read's 24-year biopharmaceutical career spans Global Research and Development, Medical Affairs, Alliance Management, Commercial and Business Development and Equity Investing. All leadership roles have included driving transformational change within organizations to accelerate top and bottom line growth, and diversification of company portfolios. Ms. Read's therapy area expertise includes Psychiatry (inventorship of MYDAYIS), Gastroenterology, Oncology & Pain, Infectious Disease, Immunology and Rare Diseases. Ms. Read's industry appointments include the last 6.5 years with CSL (CSL:ASX) as global VP, Corporate Strategy and Business Development, 7.5 years with AstraZeneca/MedImmune (AZN) in a variety of Medical Affairs, Commercial and Business Development roles, and over 6 years with Shire PLC in R&D and Global Medical Affairs (including inventing, developing and launching new treatments for ADHD).

Stephanie holds a M.Sc. in Biotechnology from The Johns Hopkins University and a B.Sc. in Biology from Virginia Tech.

Danny Villeneuve

Danny Villeneuve serves as Chief Commercial Officer of Ironshore Pharmaceuticals, responsible for leading the commercial team, including marketing, sales, sales support, sales training and associated capabilities.

Danny has more than 20 years of operational and commercial leadership experience in the biopharmaceutical industry, including 13 years where he was directly involved in the commercialization of multiple ADHD medications both in the US and global market. In addition to ADHD, Danny commercialized products in the CNS, GI, diabetes and obesity markets

Danny earned his Bachelor of Science in Medical Biology at Université du Québec in Canada.

Dr. Randy Sallee

Dr. Randy Sallee serves as the Company's Chief Medical Officer. Dr. Sallee has extensive research experience in both preclinical and clinical drug development. His administrative posts have included positions of Vice Chairman of the Department and Division Chief of Child Psychiatry at Cincinnati Children's Hospital Medical Center. As a leader in pediatric clinical pharmacology, Dr. Sallee founded the Pediatric Pharmacology Research Unit (PPRU) at Cincinnati Children's Hospital and is credited with supporting pediatric labeling for well over 50 marketed drugs in a wide range the therapeutic areas. Dr. Sallee has expertise in Orphan Drug Development, and has worked to bring new therapies to market to treat Prader Willi, Tourette Syndrome, Frontotemporal Dementia and Rett Syndrome.

Dr. Sallee is the author of over one hundred publications in refereed scientific journals whose research has been funded by the National Institutes of Health since 1990.

Dr. Sallee holds doctorates in pharmacology (University of Pittsburgh) and medicine (SIU School of Medicine) and is Board Certified in Psychiatry, Child Psychiatry and Clinical Pharmacology.

Lewis E. Warrington, MD

Lewis E. Warrington, MD, is Vice President and Head of Medical Affairs responsible for developing and managing medical strategy and supportive tactics for commercialized brands as well as all other Medical Affairs activities including Field Medical.

Lewis most recently served as the Medical Affairs Strategic Lead at Merck responsible for the development of medical strategy for CNS and immunologic products. Prior to his time at Merck, Lewis was VP and Head of the CNS Medical Unit at Novartis with responsibility for various CNS products in ADHD, schizophrenia, and Alzheimer’s Disease. Before joining Novartis, Lewis was a Senior Medical Director in Medical Affairs at Sanofi responsible for commercialized and pipeline insomnia and depression products. Prior to Sanofi, Lewis began his pharmaceutical career as a Medical Director at Pfizer working in the schizophrenia disease area.

Lewis earned his medical degree from East Carolina University School of Medicine. He completed residency training in General Adult Psychiatry at the University of Virginia and fellowship training in Child and Adolescent Psychiatry at the University of Florida. He also completed a Postdoctoral Fellowship in Neuropsychopharmacology at Mayo Clinic.





Nilay Patel

Nilay Patel is General Counsel and Chief Compliance Officer of Ironshore Pharmaceuticals.

Nilay has broad legal experience, from both private practice and as in-house counsel, supporting every stage of pharmaceutical development and commercialization, across several products and disease states.

Nilay holds a JD from Columbia Law School and a BS Biochemistry from NC State University. He is also a registered patent attorney.

Jim Fletcher

Jim serves as the Vice President of Human Resources of Ironshore Pharmaceuticals and is responsible for all areas of the HR function. He has comprehensive Human Resources leadership experience across a variety of industries including manufacturing, consumer products, medical device and pharmaceuticals. His experience includes leadership roles in Fortune 500 corporations as well as new business ventures.

Jim earned his Bachelor and Master’s degree from the Pennsylvania State University.